The Neuren (ASX:NEU) share price is falling today despite positive news

The Neuren Pharmaceuticals Ltd (ASX: NEU) share price is climbing higher today. This comes after the company announced that it received Orphan designation for its second lead drug candidate, NNZ-2591.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Neuren Pharmaceuticals Ltd (ASX: NEU) share price has changed direction today despite positive news on its drug trials

In early morning trade, the biopharma company's shares were up 2.7% to $1.50. But the Neuren share price has since sunk 3.75% to $1.41 at the time of writing. The All Ordinaries Index (ASX: XAO) is also down today, currently 0.45% lower at 6992 points.

good news and bad for asx shares represented by same man pictured happy and then sad

Image source: Getty Images

A quick take on Neuren

Based in Victoria, Australia, Neuren develops therapies for an array of neurodevelopmental and neurodegenerative disorders. The company currently has 2 key drug products in the pipeline, NNZ-2566 and NNZ-2591. The first of which is aimed at treating Rett syndrome and Fragile X syndrome. Both are currently in phase 3 and phase 2 trials, respectively.

The second drug in development, NNZ-2591, is advancing to provide remedy for Phelan-McDermid, Angelman and Pitt Hopkins syndromes. Neuren is conducting phase 1 trials with plans to commence phase 2 sometime this year.

What did Neuren announce?

Neuren has been granted received three Orphan designations for its second lead drug candidate, NNZ-2591. This treats Phelan-McDermid, Angelman and Pitt Hopkins syndromes. 

The favourable decision from the European Commission was based on the recommendations of the European Medicines Agency (EMA).

Orphan designation relates to a company receiving bonus benefits from achieving incentivised targets. This includes free protocol assistance, fee reductions, and 10 years of market exclusivity within the European Union. The period can be extended with a further 2 years if the company is approved for paediatric use.

That means that no other similar product can be granted a marketing authorisation approval from the EMA or EU countries.

About the Neuren share price

The Neuren share price has fallen more than 45% in the past 12 months.

The company's shares hit a multi-year high of $3.04 in February before COVID-19 sent shockwaves throughout the world. The result left the Neuren share price plummeting to a 52-week low of 96.5 cents.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Market News

Broker written in white with a man drawing a yellow underline.
Broker Notes

Top brokers name 3 ASX shares to buy next week

Brokers gave buy ratings to these ASX shares last week. Why are they bullish?

Read more »

A boy bounds after a big colourful bouncing ball in a grassy field.
Share Market News

ASX 200 energy shares lead and market finally cracks 8-day losing streak

The ASX 200's painful 8-day slide finally ended on Friday.

Read more »

Business people discussing project on digital tablet.
Broker Notes

Buy, hold, sell: Mesoblast, Mineral Resources, and Woolworths shares

Analysts have given their verdict on these shares. Let's see what they are saying.

Read more »

A young man punches the air in delight as he reacts to great news on his mobile phone.
Broker Notes

These top ASX 200 shares could rise 30% to 40%

Analysts are predicting big things from these shares. Let's find out why.

Read more »

Stacks of coins in a row with each higher than the last, and a person standing on top of each one watching them grow.
Dividend Investing

How I'd invest $2,000 in high-yield ASX 300 shares

I rate these businesses as strong buys for the long-term.

Read more »

A rueful woman tucks into a sweet pie as she contemplates a decision with regret.
Share Fallers

The worst 4 ASX 200 stocks to buy and hold in April unmasked

Investors sent these four ASX 200 stocks tumbling 21% to 44% in April.

Read more »

A man sitting at a computer is blown away by what he's seeing on the screen, hair and tie whooshing back as he screams argh in panic.
Share Fallers

Why these top ASX shares sank 10%+ in April

It was a tough month for these popular shares.

Read more »

A man in his office leans back in his chair with his hands behind his head looking out his window at the city, sitting back and relaxed, confident in his ASX share investments for the long term.
Broker Notes

Buy, hold, sell: Netwealth, PLS, and Reliance shares

Morgans has given its verdict on these shares. Let's see what the broker is saying.

Read more »